← 論文一覧に戻る

Astrazeneca's Sustainability Leadership: Pioneering NetZero Healthcare Innovation in the UK Pharmaceutical Industry

アストラゼネカのサステナビリティ・リーダーシップ：英国製薬業界におけるネットゼロ医療イノベーションの先駆け (AI 翻訳)

Pappu, Vamsi Lakshman, Min, May Thandar, Cameron-Goddard, Luke, Farhana, Rukaiyah, Janjua, Javaria, Suthakaran, Subaram, Uddin, Zohaib

Zenodoプレプリント2026-08-16#Scope 3経営インパクト: 調達リスク対象セクター: pharmaceutical
DOI: 10.6084/m9.figshare.33265254
原典: https://zenodo.org/records/21967019
📄 PDF

🤖 gxceed AI 要約

日本語

本ポスターは、英国製薬セクターにおけるアストラゼネカのサステナビリティ戦略とNHSネットゼロ2040ロードマップとの整合性を分析する。同社は2015年以降Scope1・2排出量を約68%削減し、低炭素研究施設や次世代吸入器プロペラントへの投資を進めている。一方、老朽工場の改修、高額な初期費用、複雑なScope3排出、規制障壁、2028年からの製品別炭素データ要件などの課題が残る。

English

This poster analyzes AstraZeneca's sustainability strategy in the UK pharmaceutical sector and its alignment with the NHS Net Zero 2040 roadmap. The company has cut Scope 1 and 2 emissions by ~68% since 2015 and invested in low-carbon facilities and next-generation inhaler propellants. Challenges remain: retrofitting old factories, high upfront costs, complex Scope 3 emissions, regulatory barriers, and 2028 product-level carbon data requirements.

Unofficial AI-generated summary based on the public title and abstract. Not an official translation.

📝 gxceed 編集解説 — Why this matters

日本のGX文脈において

日本ではSSBJ開示義務化が迫る中、製薬業界のScope3対応やサプライチェーン排出量算定の実例として参考になる。NHS調達要件が企業の競争優位性に直結する構図は、日本の医療機関や調達制度改革にも示唆を与える。

In the global GX context

This case illustrates how public procurement mandates (NHS Net Zero Supplier Roadmap) drive corporate decarbonization, relevant to global supply-chain disclosure trends under CSRD and SEC rules. It offers a concrete example of Scope 3 management in the pharmaceutical sector, which is often overlooked in climate disclosure scholarship.

👥 読者別の含意

🔬研究者:製薬業界のScope3排出量算定とサプライチェーン関与の実践的課題を理解するためのケーススタディ。

🏢実務担当者:NHSや類似の調達要件に対応するための炭素削減計画とサプライヤーエンゲージメントの参考。

🏛政策担当者:公共調達を通じた産業 decarbonization の政策効果と、製品別炭素データ要件の実装課題を示す。

📄 Abstract（原文）

This poster highlights AstraZeneca’s leadership in sustainability within the UK pharmaceutical sector and its alignment with the NHS Net Zero 2040 roadmap. Medicines account for around 25% of the NHS’s carbon footprint, so pharmaceutical companies have a crucial role in decarbonising healthcare. Under the NHS Net Zero Supplier Roadmap, all suppliers must now show carbon‑reduction plans, pushing companies to change how they produce and deliver medicines. The shift affects key stakeholders: NHS England, which drives greener procurement; AstraZeneca’s UK sites and employees, who must adopt eco‑friendly production; supply‑chain and research partners, who risk losing contracts if they don’t align; and patients, who may see reformulated or repackaged products. AstraZeneca is setting an example. It has cut Scope 1 and 2 emissions by about 68% since 2015, invested in a low‑carbon Cambridge Discovery Centre, and is developing next‑generation inhaler propellants with far lower global warming potential. These actions strengthen its NHS supplier credentials and investor confidence while supporting system‑wide decarbonisation. Five main challenges remain: retrofitting old factories with limited expertise; high upfront costs under NHS price controls; complex Scope 3 emissions across global supply chains, worsened by Brexit; regulatory barriers that can slow green innovation; and new 2028 requirements for product‑level carbon data, which are hard to measure accurately. In conclusion, AstraZeneca’s strategy shows how environmental responsibility can create competitive advantage even in a highly regulated market. Strong progress and science‑based targets support compliance and ESG performance, with future work focused on tackling Scope 3 emissions through supply‑chain engagement, ambitious targets, and continued investment in infrastructure and R&D.

🔗 Provenance — このレコードを発見したソース

🔔 こうした論文の新着を逃したくない方は キーワードアラート に登録（無料・3キーワードまで）。

gxceed は公開メタデータに基づく研究支援データセットです。要約・翻訳・解説は AI 支援で生成されています。 最終的な解釈・検証は利用者が原典資料に基づいて行うことを前提とします。